Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11610) 11610
Publication (622) 622
Newsletter (91) 91
Book Review (36) 36
Newspaper Article (34) 34
Book / eBook (27) 27
Dissertation (12) 12
Conference Proceeding (9) 9
Book Chapter (5) 5
Data Set (5) 5
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10828) 10828
female (6164) 6164
male (6091) 6091
index medicus (5855) 5855
middle aged (5339) 5339
cancer (4861) 4861
oncology (4828) 4828
stomach neoplasms - pathology (4772) 4772
stomach cancer (4620) 4620
aged (4589) 4589
gastric cancer (3806) 3806
adult (3539) 3539
stomach neoplasms - immunology (3046) 3046
prognosis (2148) 2148
gastroenterology & hepatology (2072) 2072
stomach neoplasms - genetics (2042) 2042
medicine & public health (1950) 1950
stomach neoplasms - surgery (1767) 1767
aged, 80 and over (1745) 1745
carcinoma (1741) 1741
animals (1700) 1700
surgery (1687) 1687
gastroenterology (1663) 1663
analysis (1631) 1631
metastasis (1600) 1600
stomach neoplasms - metabolism (1560) 1560
expression (1552) 1552
pathology (1527) 1527
immunohistochemistry (1498) 1498
medicine (1483) 1483
tumors (1464) 1464
research article (1439) 1439
research (1415) 1415
cell line, tumor (1301) 1301
cancer research (1298) 1298
surgical oncology (1293) 1293
risk factors (1208) 1208
neoplasm staging (1195) 1195
science (1193) 1193
stomach neoplasms - drug therapy (1170) 1170
mice (1155) 1155
multidisciplinary sciences (1146) 1146
chemotherapy (1137) 1137
health aspects (1135) 1135
stomach neoplasms - mortality (1106) 1106
gene expression (1091) 1091
helicobacter pylori (1088) 1088
stomach (1084) 1084
adenocarcinoma (1049) 1049
abdominal surgery (1039) 1039
adenocarcinoma - pathology (989) 989
immunology (987) 987
genetic aspects (976) 976
survival (951) 951
proteins (928) 928
care and treatment (924) 924
medical prognosis (887) 887
retrospective studies (877) 877
stomach neoplasms - diagnosis (874) 874
apoptosis (865) 865
stomach neoplasms - microbiology (838) 838
gastrectomy (829) 829
treatment outcome (819) 819
development and progression (786) 786
patients (784) 784
gene expression regulation, neoplastic (776) 776
oncology, experimental (739) 739
risk (735) 735
lymphatic metastasis (719) 719
studies (699) 699
stomach neoplasms - therapy (676) 676
survival rate (663) 663
follow-up studies (660) 660
diagnosis (658) 658
genes (655) 655
case-control studies (640) 640
helicobacter infections - complications (639) 639
cancers and neoplasms (638) 638
cell biology (637) 637
gastric mucosa - pathology (634) 634
cells (604) 604
metastases (590) 590
medical research (579) 579
stomach neoplasms - blood (575) 575
helicobacter pylori - immunology (574) 574
infection (567) 567
cell proliferation (566) 566
breast-cancer (565) 565
biomarkers (562) 562
survival analysis (551) 551
cancer therapies (546) 546
adenocarcinoma - immunology (539) 539
neoplasm invasiveness (536) 536
stomach neoplasms - epidemiology (525) 525
biomedicine (519) 519
biology (516) 516
multivariate analysis (506) 506
colorectal-cancer (502) 502
epidemiology (499) 499
colorectal cancer (497) 497
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (25) 25
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Credit Valley Hospital - Reference (1) 1
Gerstein Science - Reference (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10635) 10635
Japanese (423) 423
Chinese (229) 229
Russian (229) 229
German (66) 66
French (49) 49
Spanish (36) 36
Polish (35) 35
Italian (33) 33
Czech (4) 4
Korean (4) 4
Romanian (4) 4
Croatian (3) 3
Hungarian (3) 3
Bulgarian (2) 2
Danish (2) 2
Dutch (2) 2
Finnish (2) 2
Swedish (2) 2
Portuguese (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Increase of Regulatory T Cells in the Peripheral Blood of Cancer Patients
by Anna Maria Wolf and Dominik Wolf and Michael Steurer and Guenther Gastl and Eberhard Gunsilius and Beatrix Grubeck-Loebenstein
Clinical Cancer Research, ISSN 1078-0432, 02/2003, Volume 9, Issue 2, pp. 606 - 612
Purpose: T cells constitutively expressing both CD4 and CD25are essential for maintenance of self-tolerance and therefore have been referred to as regulatory T... 
ONCOLOGY | POPULATION | TUMORS | Breast Neoplasms - immunology | Humans | Lung Neoplasms - pathology | Reference Values | Stomach Neoplasms - pathology | Neoplasms - blood | Killer Cells, Natural - immunology | Female | Colorectal Neoplasms - blood | Genital Neoplasms, Female - blood | Genital Neoplasms, Female - immunology | Stomach Neoplasms - immunology | Antigens, CD - blood | Lung Neoplasms - immunology | Colorectal Neoplasms - immunology | Stomach Neoplasms - blood | Breast Neoplasms - pathology | Neoplasms - immunology | Breast Neoplasms - blood | Lymphocyte Count | T-Lymphocytes - immunology | Lung Neoplasms - blood | Colorectal Neoplasms - pathology | Neoplasm Staging | Neoplasms - pathology | Genital Neoplasms, Female - pathology | Cytotoxicity, Immunologic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
by Ayers, Mark and Lunceford, Jared and Nebozhyn, Michael and Murphy, Erin and Loboda, Andrey and Kaufman, David R and Albright, Andrew and Cheng, Jonathan D and Kang, S. Peter and Shankaran, Veena and Piha-Paul, Sarina A and Yearley, Jennifer and Seiwert, Tanguy Y and Ribas, Antoni and McClanahan, Terrill K
Journal of Clinical Investigation, ISSN 0021-9738, 08/2017, Volume 127, Issue 8, pp. 2930 - 2940
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies... 
Immunohistochemistry | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Tumor Microenvironment | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Interferon-gamma - metabolism | Immune System | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Skin Neoplasms - immunology | Carcinoma - immunology | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Stomach Neoplasms - drug therapy | Stomach Neoplasms - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - metabolism | Lung Neoplasms - immunology | Pilot Projects | Sequence Analysis, RNA | Biopsy | Melanoma - immunology | Melanoma - drug therapy | ROC Curve | Carcinoma, Non-Small-Cell Lung - drug therapy | CELL LUNG-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | MELANOMA | PEMBROLIZUMAB | LIGANDS | IMMUNOTHERAPY | SAFETY | TOLERANCE | ADAPTIVE IMMUNE RESISTANCE | EXPRESSION | PD-1 protein | Lung cancer | Clinical trials | Cytotoxicity | Biology | Lymphocytes T | Cancer therapies | Metastases | Lymphocytes | Adaptation | Antigen presentation | Squamous cell carcinoma | Cytokines | Melanoma | Inflammation | Gene expression | Immune checkpoint | PD-L1 protein | Head and neck cancer | Antitumor activity | Ligands | Interferon | Chemokines | Apoptosis | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
by Gabitass, Rachel F and Annels, Nicola E and Stocken, Deborah D and Pandha, Hardev A and Middleton, Gary W
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 10/2011, Volume 60, Issue 10, pp. 1419 - 1430
We undertook a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) in pancreatic, esophageal and... 
Immunology | Medicine & Public Health | Cytokine | Interleukin-13 | Prognostic factor | Oncology | Cancer Research | Arginase | Myeloid-derived suppressor cell | Cancer | CARCINOMA PATIENTS | MECHANISM | ADENOCARCINOMA | PERIPHERAL-BLOOD | PREVALENCE | IMMUNOLOGY | MDSCS | ONCOLOGY | REGULATORY T-CELLS | ACTIVATED GRANULOCYTES | EXPRESSION | TUMOR MICROENVIRONMENT | Pancreatic Neoplasms - blood | Prognosis | Enzyme-Linked Immunosorbent Assay | Cell Separation | Esophageal Neoplasms - blood | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Interleukin-13 - immunology | Immunophenotyping | Male | Th2 Cells - immunology | Esophageal Neoplasms - immunology | Stomach Neoplasms - immunology | Flow Cytometry | Stomach Neoplasms - blood | Myeloid Cells - immunology | Pancreatic Neoplasms - immunology | Esophageal Neoplasms - mortality | Female | Pancreatic Neoplasms - mortality | Stomach Neoplasms - mortality | Interleukin-13 - blood | Medical colleges | Care and treatment | Interleukins | Analysis | Oncology, Experimental | Research | Vascular endothelial growth factor | Stomach cancer | Esophageal cancer | Enzyme-linked immunosorbent assay | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Immunogenicity of somatic mutations in human gastrointestinal cancers
by Tran, Eric and Ahmadzadeh, Mojgan and Lu, Yong-Chen and Gros, Alena and Turcotte, Simon and Robbins, Paul F and Gartner, Jared J and Zheng, Zhili and Li, Yong F and Ray, Satyajit and Wunderlich, John R and Somerville, Robert P and Rosenberg, Steven A
Science, ISSN 0036-8075, 12/2015, Volume 350, Issue 6266, pp. 1387 - 1390
It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a... 
MELANOMA | IMMUNOTHERAPY | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | INTRATUMOR HETEROGENEITY | PATIENT | ANTI-PD-1 | IDENTIFICATION | NIVOLUMAB | T-CELLS | IPILIMUMAB | Immunodominant Epitopes - immunology | ras Proteins - genetics | Immunotherapy - methods | Proto-Oncogene Proteins p21(ras) | Gastrointestinal Neoplasms - genetics | Humans | Middle Aged | Male | Proto-Oncogene Proteins - genetics | Gastrointestinal Neoplasms - therapy | ras Proteins - immunology | Gastrointestinal Neoplasms - immunology | HLA-C Antigens - immunology | Proto-Oncogene Proteins - immunology | Cell Line, Tumor | Adult | Female | Receptors, Antigen, T-Cell - immunology | HLA-C Antigens - genetics | Immunodominant Epitopes - genetics | Mutation | CD8-Positive T-Lymphocytes - immunology | Precision Medicine - methods | Lymphocytes, Tumor-Infiltrating - immunology | Antibody diversity | Research | T cells | Gastrointestinal cancer | Analysis | Lymphocytes | Stomach cancer | Immunotherapy | Immune systems | Mutations | Receptors | Human behavior | Patients | Tumors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
by Ogitani, Yusuke and Hagihara, Katsunobu and Oitate, Masataka and Naito, Hiroyuki and Agatsuma, Toshinori
Cancer Science, ISSN 1347-9032, 07/2016, Volume 107, Issue 7, pp. 1039 - 1046
Antibody–drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic... 
topoisomerase I inhibitor | T‐DM | HER2 | bystander killing | Antibody‐drug conjugate | T-DM | Antibody-drug conjugate | HODGKINS LYMPHOMA | GEMTUZUMAB OZOGAMICIN | ADVANCED BREAST-CANCER | BRENTUXIMAB VEDOTIN | ACUTE MYELOID-LEUKEMIA | TRASTUZUMAB EMTANSINE | CHALLENGES | THERAPY | ONCOLOGY | EXPRESSION | CATHEPSIN-B | Receptor, ErbB-2 - genetics | Breast Neoplasms - immunology | Humans | Stomach Neoplasms - pathology | Maytansine - pharmacology | Immunoconjugates - immunology | Breast Neoplasms - enzymology | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Neoplasms - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Female | Camptothecin - immunology | Receptor, ErbB-2 - immunology | Camptothecin - analogs & derivatives | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Maytansine - analogs & derivatives | Neoplasms - enzymology | Stomach Neoplasms - immunology | Animals | Breast Neoplasms - genetics | Bystander Effect - drug effects | Breast Neoplasms - pathology | Mice, Nude | Neoplasms - immunology | Cell Membrane Permeability - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Antibodies, Monoclonal, Humanized - immunology | Neoplasms - pathology | Camptothecin - pharmacology | Maytansine - immunology | Trastuzumab | Viral antibodies | Epidermal growth factor | Imaging systems | Antibodies | Permeability | Drug therapy | Biopharmaceutics | Tumors | Antigens | Hematology | Laboratories | Toxicity | DNA topoisomerase | Polymerization | Clinical trials | Cytotoxicity | Breast cancer | ErbB-2 protein | Stomach cancer | Hypotheses | Antitumor agents | Xenografts | Antitumor activity | Lymphomas | Drug dosages | Payloads | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
by Murahashi, Mutsunori and Hijikata, Yasuki and Yamada, Kazunari and Tanaka, Yoshihiro and Kishimoto, Junji and Inoue, Hiroyuki and Marumoto, Tomotoshi and Takahashi, Atsushi and Okazaki, Toshihiko and Takeda, Kazuyoshi and Hirakawa, Masakazu and Fujii, Hiroshi and Okano, Shinji and Morita, Masaru and Baba, Eishi and Mizumoto, Kazuhiro and Maehara, Yoshihiko and Tanaka, Masao and Akashi, Koichi and Nakanishi, Yoichi and Yoshida, Koji and Tsunoda, Takuya and Tamura, Kazuo and Nakamura, Yusuke and Tani, Kenzaburo
Clinical Immunology, ISSN 1521-6616, 2016, Volume 166-167, pp. 48 - 58
Abstract We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with... 
Allergy and Immunology | Translational research | Five-peptide cancer vaccine | Cyclophosphamide | Regulatory T cells | INTERLEUKIN-2 | IMMUNE-RESPONSE | LUNG | TESTIS ANTIGENS | IMMUNOLOGY | EPITOPE-PEPTIDES | IDENTIFICATION | BREAST-CANCER | IMMUNOTHERAPY | COLORECTAL-CANCER | REGULATORY T-CELLS | Lung Neoplasms - drug therapy | Cyclophosphamide - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | HLA-A24 Antigen - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epitopes - administration & dosage | Male | Cyclophosphamide - adverse effects | Peptides - administration & dosage | Dose-Response Relationship, Drug | Epitopes - immunology | Neoplasms - genetics | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Colorectal Neoplasms - drug therapy | Leukopenia - chemically induced | Aged, 80 and over | Adult | Female | Vaccines, Subunit - adverse effects | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | HLA-A24 Antigen - immunology | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Peptides - immunology | Kaplan-Meier Estimate | Cancer Vaccines - adverse effects | Treatment Outcome | Cyclophosphamide - immunology | Vaccines, Subunit - immunology | Stomach Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - immunology | Neoplasms - drug therapy | Stomach Neoplasms - immunology | Cancer Vaccines - immunology | Lung Neoplasms - immunology | Colorectal Neoplasms - immunology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms - immunology | Vaccines, Subunit - administration & dosage | T-Lymphocytes - immunology | Aged | Cancer vaccines | Antigens | Chemotherapy | Peptides | Vaccination | Colorectal cancer | Clinical trials | Product development | T cells | Cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy
by Giampieri, Riccardo and Maccaroni, Elena and Mandolesi, Alessandra and Del Prete, Michela and Andrikou, Kalliopi and Faloppi, Luca and Bittoni, Alessandro and Bianconi, Maristella and Scarpelli, Marina and Bracci, Raffaella and Scartozzi, Mario and Cascinu, Stefano
Gastric Cancer, ISSN 1436-3291, 1/2017, Volume 20, Issue 1, pp. 156 - 163
The microsatellite-instable gastric cancer subtype, because of its supposed high antigenic potential, is a promising candidate for immunotherapy. We analyzed... 
Chemotherapy | Prognosis | Medicine & Public Health | Mismatch repair | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | Microsatellite instability | Surgical Oncology | Gastric cancer | ADJUVANT CHEMOTHERAPY | EFFICACY | TUMOR MICROSATELLITE-INSTABILITY | BENEFIT | ONCOLOGY | COLORECTAL-CANCER | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | Lung Neoplasms - drug therapy | Microsatellite Instability | Follow-Up Studies | Humans | Male | Stomach Neoplasms - pathology | DNA Mismatch Repair - genetics | Cisplatin - administration & dosage | Organoplatinum Compounds - administration & dosage | Peritoneal Neoplasms - drug therapy | Fluorouracil - administration & dosage | Lung Neoplasms - secondary | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Liver Neoplasms - secondary | Peritoneal Neoplasms - immunology | Neutrophils - pathology | Peritoneal Neoplasms - secondary | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Liver Neoplasms - genetics | Biomarkers, Tumor - analysis | Liver Neoplasms - drug therapy | Liver Neoplasms - immunology | Survival Rate | Combined Modality Therapy | Stomach Neoplasms - drug therapy | Stomach Neoplasms - immunology | Lung Neoplasms - immunology | Lymphocytes - pathology | Lymphocytes, Tumor-Infiltrating - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Aged | Neoplasm Staging | Lymphocytes, Tumor-Infiltrating - immunology | Cancer patients | Care and treatment | Immune response | Patient outcomes | Immunotherapy | Metastasis | Stomach cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Dual Roles for Immunity in Gastrointestinal Cancers
by Cristina Ferrone and Glenn Dranoff
Journal of Clinical Oncology, ISSN 0732-183X, 09/2010, Volume 28, Issue 26, pp. 4045 - 4051
Histopathologic examination reveals that most human tumors are associated with diverse immune cell infiltrates, but the roles of host reactions in disease... 
HEPATOCELLULAR-CARCINOMA | ONCOLOGY | COLORECTAL-CANCER | INTERLEUKIN-10 RECEPTOR | ULCERATIVE-COLITIS | FAMILIAL ADENOMATOUS POLYPOSIS | COLITIS-ASSOCIATED CANCER | LYMPHOCYTES INDUCE | NF-KAPPA-B | HELICOBACTER-PYLORI | T-CELLS | Tumor Escape | Humans | Liver Neoplasms - immunology | Gastrointestinal Neoplasms - therapy | Immunity | Gastrointestinal Neoplasms - etiology | Stomach Neoplasms - immunology | Gastrointestinal Neoplasms - immunology | Liver Neoplasms - etiology | Inflammation - complications | Colorectal Neoplasms - etiology | Colorectal Neoplasms - immunology | T-Lymphocytes - immunology | Carcinoma, Hepatocellular - etiology | Carcinoma, Hepatocellular - immunology | Stomach Neoplasms - etiology | Bon | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text An overview of the association between allergy and cancer
by Turner, Michelle C and Chen, Yue and Krewski, Daniel and Ghadirian, Parviz
International Journal of Cancer, ISSN 0020-7136, 06/2006, Volume 118, Issue 12, pp. 3124 - 3132
Numerous epidemiological studies have evaluated some aspect of the association between a history of allergy and cancer occurrence. In this article, an overview... 
epidemiology | allergy | neoplasms | etiology | Allergy | Etiology | Epidemiology | Neoplasms | KILLER-CELL-ACTIVITY | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | PRIOR MEDICATION USE | POPULATION-BASED COHORT | NON-HODGKINS-LYMPHOMA | CHRONIC ANTIGENIC-STIMULATION | CHRONIC LYMPHOCYTIC-LEUKEMIA | FRANCISCO BAY AREA | PREVIOUS LUNG-DISEASE | ADULT BRAIN-TUMOR | Humans | Glioma - immunology | Hypersensitivity - immunology | Genital Neoplasms, Female - immunology | Esophageal Neoplasms - immunology | Case-Control Studies | Stomach Neoplasms - immunology | Lung Neoplasms - immunology | Brain Neoplasms - immunology | Colorectal Neoplasms - immunology | Confounding Factors (Epidemiology) | Neoplasms - immunology | Thyroid Neoplasms - immunology | Pancreatic Neoplasms - immunology | Urinary Bladder Neoplasms - immunology | Female | Hypersensitivity - epidemiology | Hematologic Neoplasms - immunology | Research Design | Neoplasms - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
by Ott, Marion G and Marmé, Frederik and Moldenhauer, Gerhard and Lindhofer, Horst and Hennig, Michael and Spannagl, Rolf and Essing, Mirko M and Linke, Rolf and Seimetz, Diane
International Journal of Cancer, ISSN 0020-7136, 05/2012, Volume 130, Issue 9, pp. 2195 - 2203
The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer... 
catumaxomab | malignant ascites | trifunctional antibody | clinical outcome | humoral response | SURVIVAL | ACTIVATION | INDUCTION | CANCER | BENEFIT | LASTING ANTITUMOR IMMUNITY | THERAPY | ONCOLOGY | ACCESSORY CELLS | MONOCLONAL-ANTIBODIES | T-CELLS | Immunotherapy - methods | Immunity, Humoral - immunology | Peritoneal Neoplasms - blood | Humans | Ovarian Neoplasms - pathology | Antibodies, Monoclonal - therapeutic use | Stomach Neoplasms - pathology | Peritoneal Neoplasms - drug therapy | Antibodies, Bispecific - administration & dosage | Ascites - blood | Ascites - immunology | Female | Ovarian Neoplasms - drug therapy | Peritoneal Neoplasms - immunology | Peritoneal Neoplasms - pathology | Antibodies, Anti-Idiotypic - blood | Ovarian Neoplasms - blood | Rats | Treatment Outcome | Stomach Neoplasms - drug therapy | Antibodies, Bispecific - immunology | Ascites - drug therapy | Biomarkers, Pharmacological - blood | Stomach Neoplasms - immunology | Paracentesis - methods | Animals | Stomach Neoplasms - blood | Survival Analysis | Mice | Ovarian Neoplasms - immunology | Medical research | Clinical outcomes | Cancer Therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights